Methods of preparing cytotoxic benzodiazepine derivatives
US-2017050985-A1 · Feb 23, 2017 · US
US10370389B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10370389-B2 |
| Application number | US-201715837832-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 11, 2017 |
| Priority date | Jul 21, 2015 |
| Publication date | Aug 6, 2019 |
| Grant date | Aug 6, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
Opening claim text (preview).
The invention claimed is: 1. A method of preparing a compound of formula (3A), or a salt thereof, said method comprising the steps of: (i) introducing an alcohol protecting group onto one of the primary alcohols of a compound of formula (1) by reacting the compound of formula (1A) with an alcohol protecting reagent, to form a compound of formula (2A), or a salt thereof; and (ii) reacting a halogenating reagent, a sulfonating reagent or an esterification reagent with the compound of formula (2A), wherein: P 1 is an alcohol protecting group; and, X 1 is a leaving group selected from the group consisting of: —Br, —I, —Cl, a sulfonate ester, and an activated ester. 2. The method of claim 1 , wherein the sulfonate ester represented by X 1 is mesylate, tosylate, brosylate, or triflate. 3. The method of claim 2 , wherein the sulfonate ester represented by X 1 is mesylate. 4. The method of claim 1 , wherein the method comprising reacting the compound of formula (2A) with a sulfonating reagent in the presence of a non-nucleophilic base. 5. The method of claim 4 , wherein the non-nucleophilic base is triethylamine, imidazole, diisopropylethylamine, pyridine, 2,6-lutidine, dimethylformamide, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), or tetramethylpiperidine. 6. The method of claim 5 , wherein the non-nucleophilic base is triethylamine or diisopropylethylamine. 7. The method of claim 4 , wherein the sulfonating reagent is methanesulfonic anhydride or methanesulfonyl chloride (MsCl). 8. The method of claim 1 , wherein the method comprising reacting a halogenating reagent with the compound of formula (2A) and the halogenating reagent is methanesulfonyl chloride, thionyl chloride, bromine, hydrobromic acid, carbon tetrabromide, phosphorus tribromide, potassium bromide, hydroiodic acid, iodine, carbon tetraiodide, phosphorus triiodide, sodium iodide, or potassium iodide. 9. A method of preparing a compound of formula (IA), or a pharmaceutically acceptable salt thereof, said method comprising the steps of: (1) introducing an alcohol protecting group onto one of the primary alcohols of a compound of formula (1A), to form a compound of formula (2A), (2) reacting the compound of formula (2A) with a halogenating reagent, a sulfonating reagent or an esterification reagent to form a compound of formula (3A), (3) reacting the compound of formula (3A) with a monomer compound of the formula (a 1 ), to form a compound of formula (4A), (4) reacting the compound of formula (4A) with an imine reducing agent to form a compound of formula (5A), (5) reacting the compound of formula (5A) with an alcohol deprotecting reagent to form a compound of formula (6A), (6) reacting the compound of formula (6A) with a second halogenating reagent, a second sulfonating reagent or a second esterification reagent to form a compound of formula (7A), and (7) reacting the compound of formula (7A) with a monomer compound of the formula (b1), to form the compound of formula (IA); wherein: P 1 is an alcohol protecting group; and, X 1 and X 2 are each independently a leaving group selected from the group consisting of: —Br, —I, —Cl, a sulfonate ester and an activated ester. 10. A method of preparing a compound of formula (IA), or a pharmaceutically acceptable salt thereof, said method comprising the steps of: (1) introducing an alcohol protecting group onto one of the primary alcohols of the compound of formula (1A), to form a compound of formula (2A), (2) reacting a halogenating reagent, a sulfonating reagent or an esterification reagent with the compound of formula (2) to form a compound of formula (3A), (3) reacting the compound of formula (3A) with a monomer compound of the formula (b1), to form a compound of formula (8A), (4) reacting the compound of formula (8A) with an alcohol deprotecting reagent to form a compound of formula (9A), (5) reacting a second halogenating reagent, a second sulfonating reagent or a second esterification reagent with the compound of formula (9A) to form a compound of formula (10A), (6) reacting the compound of formula (10A) with a monomer compound of the formula (d 1 ) to form a compound of formula (18A), (7) when P 3 is an amine protecting group; reacting the compound of formula (18A) with an amine deprotecting reagent to form the compound of formula (IA), wherein: P 3 is H or an amine protecting group; P 1 is an alcohol protecting group; and X 1 and X 2 are each independently a leaving group selected from the group consisting of: —Br, —I, —Cl, a sulfonate ester, and an activated ester. 11. The method of claim 10 , wherein P 3 is H and the compound of (10A) is reacted with the monomer compound of (d 1 ) to form the compound of (IA). 12. The method of claim 1 , wherein the alcohol protecting group is a silyl protecting group. 13. The method of claim 12 , wherein the silyl protecting group is dimethylisopropylsilyl, diethylisopropylsilyl, dimethylhexylsilyl, trimethylsilyl, triisopropylsilyl, tribenzylsilyl, triphenylsilyl, 2-norbornyldimethylsilyl, te
Antineoplastic agents · CPC title
by reaction of hydroxy compounds with sulfonic acids or derivatives thereof · CPC title
Ortho-condensed systems · CPC title
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
and aliphatic · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.